<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35527777</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1792-1082</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Oncology letters</Title>
          <ISOAbbreviation>Oncol Lett</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Perphenazine and prochlorperazine decrease glioblastoma U-87 MG cell migration and invasion: Analysis of the ABCB1 and ABCG2 transporters, E-cadherin, α-tubulin and integrins (α3, α5, and β1) levels.</ArticleTitle>
        <Pagination>
          <StartPage>182</StartPage>
          <MedlinePgn>182</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">182</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3892/ol.2022.13302</ELocationID>
        <Abstract>
          <AbstractText>Glioblastoma multiforme is the most frequent type of malignant brain tumor, and is one of the most lethal and untreatable human tumors with a very poor survival rate. Therefore, novel and effective strategies of treatment are required. Integrins play a crucial role in the regulation of cellular adhesion and invasion. Integrins and α-tubulin are very important in cell migration, whereas E-cadherin plays a main role in tumor metastasis. Notably, drugs serve a crucial role in glioblastoma treatment; however, they have to penetrate the blood-brain barrier (BBB) to be effective. ABC transporters, including ATP binding cassette subfamily B member 1 (ABCB1) and ATP binding cassette subfamily G member 2 (ABCG2), are localized in the brain endothelial capillaries of the BBB, have a crucial role in the development of multidrug resistance and are modulated by phenothiazine derivatives. The impact of perphenazine and prochlorperazine on the motility of human Uppsala 87 malignant glioma (U87-MG) cells was evaluated using a wound-healing assay, cellular migration and invasion were assessed by Transwell assay, and the protein expression levels of ABCB1, ABCG2, E-cadherin, α-tubulin and integrins were determined by western blotting. The present study explored the effects of perphenazine and prochlorperazine on the levels of ABCB1, ABCG2, E-cadherin, α-tubulin and integrins (α3, α5, and β1), as well as on the migratory and invasive ability of U87-MG cells. The results suggested that perphenazine and prochlorperazine may modulate the expression levels of multidrug resistance proteins (they decreased ABCB1 and increased ABCG2 expression), E-cadherin, α-tubulin and integrins, and could impair the migration and invasion of U-87 MG cells. In conclusion, the decrease in migratory and invasive ability following treatment with phenothiazine derivatives due to the increase in ABCG2 and E-cadherin expression, and decrease in α-tubulin and integrins expression, may suggest that research on perphenazine and prochlorperazine in the treatment of glioblastoma is worth continuing.</AbstractText>
          <CopyrightInformation>Copyright: © Otręba et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Otręba</LastName>
            <ForeName>Michał</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Drug Technology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, 41-200 Sosnowiec, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stojko</LastName>
            <ForeName>Jerzy</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Toxicology and Bioanalysis, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, 41-200 Sosnowiec, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kabała-Dzik</LastName>
            <ForeName>Agata</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, 41-200 Sosnowiec, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rzepecka-Stojko</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Drug Technology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, 41-200 Sosnowiec, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Oncol Lett</MedlineTA>
        <NlmUniqueID>101531236</NlmUniqueID>
        <ISSNLinking>1792-1074</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ABCB1</Keyword>
        <Keyword MajorTopicYN="N">ABCG2</Keyword>
        <Keyword MajorTopicYN="N">E-cadherin</Keyword>
        <Keyword MajorTopicYN="N">U-87 MG cells</Keyword>
        <Keyword MajorTopicYN="N">integrins (α3 α5 and β1)</Keyword>
        <Keyword MajorTopicYN="N">invasion</Keyword>
        <Keyword MajorTopicYN="N">migration</Keyword>
        <Keyword MajorTopicYN="N">perphenazine</Keyword>
        <Keyword MajorTopicYN="N">prochlorperazine</Keyword>
        <Keyword MajorTopicYN="N">α-tubulin</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>9</Day>
          <Hour>3</Hour>
          <Minute>46</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35527777</ArticleId>
        <ArticleId IdType="pmc">PMC9073583</ArticleId>
        <ArticleId IdType="doi">10.3892/ol.2022.13302</ArticleId>
        <ArticleId IdType="pii">OL-23-06-13302</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Alphandéry E. Glioblastoma treatments: An account of recent industrial developments. Front Pharmacol. 2018;9:879. doi: 10.3389/fphar.2018.00879.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2018.00879</ArticleId>
            <ArticleId IdType="pmc">PMC6147115</ArticleId>
            <ArticleId IdType="pubmed">30271342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee SU. Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pacific J Cancer Prev. 2017;18:3–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5563115</ArticleId>
            <ArticleId IdType="pubmed">28239999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bai RY, Staedtke V, Riggins GJ. Molecular targeting of glioblastoma: Drug discovery and therapies. Trends Mol Med. 2011;17:301–312. doi: 10.1016/j.molmed.2011.01.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molmed.2011.01.011</ArticleId>
            <ArticleId IdType="pmc">PMC4101015</ArticleId>
            <ArticleId IdType="pubmed">21411370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kast RE, Ellingson BM, Marosi C, Halatsch ME. Glioblastoma treatment using perphenazine to block the subventricular zone's tumor trophic functions. J Neurooncol. 2014;116:207–212. doi: 10.1007/s11060-013-1308-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-013-1308-y</ArticleId>
            <ArticleId IdType="pubmed">24242756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wick W, Weller M, Weiler M, Batchelor T, Yung AW, Platten M. Pathway inhibition: Emerging molecular targets for treating glioblastoma. Neuro Oncol. 2011;13:566–579. doi: 10.1093/neuonc/nor039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nor039</ArticleId>
            <ArticleId IdType="pmc">PMC3107100</ArticleId>
            <ArticleId IdType="pubmed">21636705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masoumi KC, Huang X, Sime W, Mirkov A, Munksgaard Thorén M, Massoumi R, Lundgren-Åkerlund E. Integrin α10-antibodies reduce glioblastoma tumor growth and cell migration. Cancers. 2021;13:1184. doi: 10.3390/cancers13051184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13051184</ArticleId>
            <ArticleId IdType="pmc">PMC7980568</ArticleId>
            <ArticleId IdType="pubmed">33803359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ellert-Miklaszewska A, Poleszak K, Pasierbinska M, Kaminska B. Integrin signaling in glioma pathogenesis: From biology to therapy. Int J Mol Sci. 2020;21:888. doi: 10.3390/ijms21030888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21030888</ArticleId>
            <ArticleId IdType="pmc">PMC7037280</ArticleId>
            <ArticleId IdType="pubmed">32019108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malric L, Monferran S, Gilhodes J, Boyrie S, Dahan P, Skuli N, Sesen J, Filleron T, Kowalski-Chauvel A, Cohen-Jonathan Moyal E, et al.  Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: An update. Oncotarget. 2017;8:86947–86968. doi: 10.18632/oncotarget.20372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.20372</ArticleId>
            <ArticleId IdType="pmc">PMC5689739</ArticleId>
            <ArticleId IdType="pubmed">29156849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee CC, Cheng YC, Chang CY, Lin CM, Chang JY. Alpha-tubulin acetyltransferase/MEC-17 regulates cancer cell migration and invasion through epithelial-mesenchymal transition suppression and cell polarity disruption. Sci Rep. 2018;8:17477. doi: 10.1038/s41598-018-35392-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-35392-6</ArticleId>
            <ArticleId IdType="pmc">PMC6269487</ArticleId>
            <ArticleId IdType="pubmed">30504808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Na TY, Schecterson L, Mendonsa AM, Gumbiner BM. The functional activity of E-cadherin controls tumor cell metastasis at multiple steps. Proc Natl Acad Sci USA. 2020;117:5931–5937. doi: 10.1073/pnas.1918167117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1918167117</ArticleId>
            <ArticleId IdType="pmc">PMC7084067</ArticleId>
            <ArticleId IdType="pubmed">32127478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wick W, Osswald M, Wick A, Winkler F. Treatment of glioblastoma in adults. Ther Adv Neurol Disord. 2018;11:1756286418790452. doi: 10.1177/1756286418790452.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1756286418790452</ArticleId>
            <ArticleId IdType="pmc">PMC6071154</ArticleId>
            <ArticleId IdType="pubmed">30083233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartek J, Hodny Z. Dopamine signaling: Target in glioblastoma. Oncotarget. 2014;5:1116–1117. doi: 10.18632/oncotarget.1835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.1835</ArticleId>
            <ArticleId IdType="pmc">PMC4012725</ArticleId>
            <ArticleId IdType="pubmed">24657925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motohashi N, Kawase M, Satoh K, Sakagami H. Cytotoxic potential of phenothiazines. Curr Drug Targets. 2006;7:1055–1066. doi: 10.2174/138945006778226624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/138945006778226624</ArticleId>
            <ArticleId IdType="pubmed">17017885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sudeshna G, Parimal K. Multiple non-psychiatric effects of phenothiazines: A review. Eur J Pharmacol. 2010;648:6–14. doi: 10.1016/j.ejphar.2010.08.045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejphar.2010.08.045</ArticleId>
            <ArticleId IdType="pubmed">20828548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Otręba M, Kośmider L. In vitro anticancer activity of fluphenazine, perphenazine and prochlorperazine. A review. J Appl Toxicol. 2021;41:82–94. doi: 10.1002/jat.4046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jat.4046</ArticleId>
            <ArticleId IdType="pubmed">32852120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balça-Silva J, Matias D, Carmo AD, Sarmento-Ribeiro AB, Lopes MC, Moura-Neto V. Cellular and molecular mechanisms of glioblastoma malignancy: Implications in resistance and therapeutic strategies. Semin Cancer Biol. 2018;58:130–141. doi: 10.1016/j.semcancer.2018.09.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2018.09.007</ArticleId>
            <ArticleId IdType="pubmed">30266571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Otręba M, Pajor M, Warncke JD. Antimelanoma activity of perphenazine and prochlorperazine in human COLO829 and C32 cell lines. Naunyn Schmiedebergs Arch Pharmacol. 2019;392:1257–1264. doi: 10.1007/s00210-019-01668-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00210-019-01668-5</ArticleId>
            <ArticleId IdType="pubmed">31172223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atif F, Patel NR, Yousuf S, Stein DG. The synergistic effect of combination progesterone and temozolomide on human glioblastoma cells. PLoS One. 2015;10:e0131441. doi: 10.1371/journal.pone.0131441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0131441</ArticleId>
            <ArticleId IdType="pmc">PMC4482510</ArticleId>
            <ArticleId IdType="pubmed">26110872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yelskaya Z, Carrillo V, Dubisz E, Gulzar H, Morgan D, Mahajan SS. Synergistic inhibition of survival, proliferation, and migration of U87 cells with a combination of LY341495 and Iressa. PLoS One. 2013;8:e64588. doi: 10.1371/journal.pone.0064588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0064588</ArticleId>
            <ArticleId IdType="pmc">PMC3664620</ArticleId>
            <ArticleId IdType="pubmed">23724064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haque S, Norbert CC, Acharyya R, Mukherjee S, Kathirvel M, Patra CR. Biosynthesized silver nanoparticles for cancer therapy and in vivo bioimaging. Cancers. 2021;13:6114. doi: 10.3390/cancers13236114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13236114</ArticleId>
            <ArticleId IdType="pmc">PMC8657022</ArticleId>
            <ArticleId IdType="pubmed">34885224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sengul E, Elitas M. Single-cell mechanophenotyping in microfluidics to evaluate behavior of U87 glioma cells. Micromachines (Basel) 2020;11:845. doi: 10.3390/mi11090845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/mi11090845</ArticleId>
            <ArticleId IdType="pmc">PMC7569913</ArticleId>
            <ArticleId IdType="pubmed">32932941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kabała-Dzik A, Rzepecka-Stojko A, Kubina R, Jastrzębska-Stojko Ż, Stojko R, Wojtyczka RD, Stojko J. Migration rate inhibition of breast cancer cells treated by caffeic acid and caffeic acid phenethyl ester: An in vitro comparison study. Nutrients. 2017;9:1144. doi: 10.3390/nu9101144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/nu9101144</ArticleId>
            <ArticleId IdType="pmc">PMC5691760</ArticleId>
            <ArticleId IdType="pubmed">29048370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grada A, Otero-Vinas M, Prieto-Castrillo F, Obagi Z, Falanga V. Research techniques made simple: Analysis of collective cell migration using the wound healing assay. J Invest Dermatol. 2017;137:e11–e16. doi: 10.1016/j.jid.2016.11.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jid.2016.11.020</ArticleId>
            <ArticleId IdType="pubmed">28110712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Devereaux J, Dargahi N, Fraser S, Nurgali K, Kiatos D, Apostolopoulos V. Leucocyte-rich platelet-rich plasma enhances fibroblast and extracellular matrix activity: Implications in wound healing. Int J Mol Sci. 2020;21:6519. doi: 10.3390/ijms21186519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21186519</ArticleId>
            <ArticleId IdType="pmc">PMC7556022</ArticleId>
            <ArticleId IdType="pubmed">32900003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernhart E, Damm S, Wintersperger A, DeVaney T, Zimmer A, Raynham T, Ireson C, Sattler W. Protein kinase D2 regulates migration and invasion of U87MG glioblastoma cells in vitro. Exp Cell Res. 2013;319:2037–2048. doi: 10.1016/j.yexcr.2013.03.029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexcr.2013.03.029</ArticleId>
            <ArticleId IdType="pmc">PMC3715702</ArticleId>
            <ArticleId IdType="pubmed">23562655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Limame R, Wouters A, Pauwels B, Fransen E, Peeters M, Lardon F, De Wever O, Pauwels P. Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. PLoS One. 2012;7:e46536. doi: 10.1371/journal.pone.0046536.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0046536</ArticleId>
            <ArticleId IdType="pmc">PMC3477108</ArticleId>
            <ArticleId IdType="pubmed">23094027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li S, Li C, Ryu HH, Lim SH, Jang WY, Jung S. Bacitracin inhibits the migration of U-87 MG glioma cells via interferences of the integrin outside-in signaling pathway. J Korean Neurosurg Soc. 2016;59:106–116. doi: 10.3340/jkns.2016.59.2.106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3340/jkns.2016.59.2.106</ArticleId>
            <ArticleId IdType="pmc">PMC4783475</ArticleId>
            <ArticleId IdType="pubmed">26962415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao X, Sun Q, Dou C, Chen Q, Liu B. BMP4 inhibits glioblastoma invasion by promoting E-cadherin and claudin expression. Front Biosci (Landmark Ed) 2019;24:1060–1070. doi: 10.2741/4768.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2741/4768</ArticleId>
            <ArticleId IdType="pubmed">30844730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Otręba M, Buszman E. Perphenazine and prochlorperazine induce concentration-dependent loss in human glioblastoma cells viability. Die Pharmazie. 2018;73:19–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29441946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muriithi W, Macharia LW, Heming CP, Echevarria JL, Nyachieo A, Filho PN, Neto VM. ABC transporters and the hallmarks of cancer: Roles in cancer aggressiveness beyond multidrug resistance. Cancer Biol Med. 2020;17:253–269. doi: 10.20892/j.issn.2095-3941.2019.0284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.20892/j.issn.2095-3941.2019.0284</ArticleId>
            <ArticleId IdType="pmc">PMC7309456</ArticleId>
            <ArticleId IdType="pubmed">32587767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Li Q, Zhou L, Xie N, Nice EC, Zhang H, Huang C, Lei Y. Cancer drug resistance: Redox resetting renders a way. Oncotarget. 2016;7:42740–42761. doi: 10.18632/oncotarget.8600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.8600</ArticleId>
            <ArticleId IdType="pmc">PMC5173169</ArticleId>
            <ArticleId IdType="pubmed">27057637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta SK, Singh P, Ali V, Verma M. Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy. Oncol Rev. 2020;14:448. doi: 10.4081/oncol.2020.448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4081/oncol.2020.448</ArticleId>
            <ArticleId IdType="pmc">PMC7358983</ArticleId>
            <ArticleId IdType="pubmed">32676170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin F, de Gooijer MC, Roig EM, Buil LC, Christner SM, Beumer JH, Würdinger T, Beijnen JH, van Tellingen O. ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy. Clin Cancer Res. 2014;20:2703–2713. doi: 10.1158/1078-0432.CCR-14-0084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-0084</ArticleId>
            <ArticleId IdType="pubmed">24647572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wijaya J, Fukuda Y, Schuetz JD. Obstacles to brain tumor therapy: Key ABC transporters. Int J Mol Sci. 2017;18:2544. doi: 10.3390/ijms18122544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms18122544</ArticleId>
            <ArticleId IdType="pmc">PMC5751147</ArticleId>
            <ArticleId IdType="pubmed">29186899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan L, Lin H, Tian S, Bai D, Kong Y, Yu L. The sensitivity of glioma cells to pyropheophorbide-αmethyl ester-mediated photodynamic therapy is enhanced by inhibiting ABCG2. Lasers Surg Med. 2017;49:719–726. doi: 10.1002/lsm.22661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/lsm.22661</ArticleId>
            <ArticleId IdType="pubmed">28370217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdallah HM, Al-Abd AM, El-Dine RS, El-Halawany AM. P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review. J Adv Res. 2015;6:45–62. doi: 10.1016/j.jare.2014.11.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jare.2014.11.008</ArticleId>
            <ArticleId IdType="pmc">PMC4293676</ArticleId>
            <ArticleId IdType="pubmed">25685543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang JS, Zhu HJ, Markowitz JS, Donovan JL, Yuan HJ, Devane CL. Antipsychotic drugs inhibit the function of breast cancer resistance protein. Basic Clin Pharmacol Toxicol. 2008;103:336–341. doi: 10.1111/j.1742-7843.2008.00298.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1742-7843.2008.00298.x</ArticleId>
            <ArticleId IdType="pmc">PMC2637613</ArticleId>
            <ArticleId IdType="pubmed">18834354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wesołowska O. Interaction of phenothiazines, stilbenes and flavonoids with multidrug resistance-associated transporters, P-glycoprotein and MRP1. Acta Biochim Pol. 2011;58:433–448. doi: 10.18388/abp.2011_2209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18388/abp.2011_2209</ArticleId>
            <ArticleId IdType="pubmed">22187677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spengler G, Csonka Á, Molnár J, Amaral L. The anticancer activity of the old neuroleptic phenothiazine-type drug thioridazine. Anticancer Res. 2016;36:5701–5706. doi: 10.21873/anticanres.11153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21873/anticanres.11153</ArticleId>
            <ArticleId IdType="pubmed">27793891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdallah IM, Al-Shami KM, Yang E, Kaddoumi A. Blood-brain barrier disruption increases amyloid-related pathology in TgSwDI mice. Int J Mol Sci. 2021;22:1231. doi: 10.3390/ijms22031231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms22031231</ArticleId>
            <ArticleId IdType="pmc">PMC7865722</ArticleId>
            <ArticleId IdType="pubmed">33513818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diop NK, Hrycyna CA. N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane. Biochemistry. 2005;44:5420–5429. doi: 10.1021/bi0479858.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi0479858</ArticleId>
            <ArticleId IdType="pubmed">15807535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarafian V, Koev I, Staykov D. Mechanisms of cell resistance in glioblastoma multiforme. J IMAB. 2009;1:6–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Web page of International Union of Basic and Clinical Pharmacology. https://www.guidetopharmacology.org/  (access 08.02.2022)</Citation>
        </Reference>
        <Reference>
          <Citation>Kast RE. Adding perphenazine to increase effectiveness of standard glioblastoma chemoirradiation. J BUON. 2020;25:1676–1686.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33099901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aaberg-Jessen C, Nørregaard A, Christensen K, Pedersen CB, Andersen C, Kristensen BW. Invasion of primary glioma- and cell line-derived spheroids implanted into corticostriatal slice cultures. Int J Clin Exp Pathol. 2013;6:546–560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3606845</ArticleId>
            <ArticleId IdType="pubmed">23573302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caragher SP, Shireman JM, Huang M, Miska J, Atashi F, Baisiwala S, Hong Park C, Saathoff MR, Warnke L, Xiao T, et al.  Activation of dopamine receptor 2 prompts transcriptomic and metabolic plasticity in glioblastoma. J Neurosci. 2019;9:1982–1993. doi: 10.1523/JNEUROSCI.1589-18.2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.1589-18.2018</ArticleId>
            <ArticleId IdType="pmc">PMC6507082</ArticleId>
            <ArticleId IdType="pubmed">30651332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weissenrieder JS, Reed JL, Green MV, Moldovan GL, Koubek EJ, Neighbors JD, Hohl RJ. The dopamine D2 receptor contributes to the spheroid formation behavior of U87 glioblastoma cells. Pharmacology. 2020;105:19–27. doi: 10.1159/000502562.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000502562</ArticleId>
            <ArticleId IdType="pubmed">31645049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhat K, Saki M, Vlashi E, Cheng F, Duhachek-Muggy S, Alli C, Yu G, Medina P, He L, Damoiseaux R, et al.  The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma. Proc Natl Acad Sci USA. 2020;117:11085–11096. doi: 10.1073/pnas.1920154117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1920154117</ArticleId>
            <ArticleId IdType="pmc">PMC7245100</ArticleId>
            <ArticleId IdType="pubmed">32358191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agrawal I, Sharma N, Saxena S, Arvind S, Chakraborty D, Chakraborty DB, Jha D, Ghatak S, Epari S, Gupta T, Jha S. Dopamine induces functional extracellular traps in microglia. iScience. 2021;24:101968. doi: 10.1016/j.isci.2020.101968.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.isci.2020.101968</ArticleId>
            <ArticleId IdType="pmc">PMC7797945</ArticleId>
            <ArticleId IdType="pubmed">33458617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Z, Jiang X, Gao L, Liu X, Li J, Huang X, Zeng T. Synergistic suppression of glioblastoma cell growth by combined application of temozolomide and dopamine D2 receptor antagonists. World Neurosurg1. 2019;28:e468–e477. doi: 10.1016/j.wneu.2019.04.180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.wneu.2019.04.180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arrillaga-Romany I, Odia Y, Prabhu VV, Tarapore RS, Merdinger K, Stogniew M, Oster W, Allen JE, Mehta M, Batchelor TT, Wen PY. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Neuro Oncol. 2020;22:94–102. doi: 10.1093/neuonc/noz164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noz164</ArticleId>
            <ArticleId IdType="pmc">PMC7080220</ArticleId>
            <ArticleId IdType="pubmed">31702782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Y, Li J, Koga T, Ma J, Dhawan S, Suzuki Y, Furnari F, Prabhu VV, Allen JE, Chen CC. Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors. Neuro Oncol. 2021;23:400–411. doi: 10.1093/neuonc/noaa188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noaa188</ArticleId>
            <ArticleId IdType="pmc">PMC7992877</ArticleId>
            <ArticleId IdType="pubmed">32830856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abbruzzese C, Matteoni S, Persico M, Villani V, Paggi MG. Repurposing chlorpromazine in the treatment of glioblastoma multiforme: Analysis of literature and forthcoming steps. J Exp Clin Cancer Res. 2020;39:26. doi: 10.1186/s13046-020-1534-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-020-1534-z</ArticleId>
            <ArticleId IdType="pmc">PMC6995164</ArticleId>
            <ArticleId IdType="pubmed">32005270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech EA, Plumb D, Zakka L, Gazinska P, Liccardi G, et al.  PIM1 kinase regulates cell death, tumor growth and chemotherapy response revealing a novel target in triple-negative breast cancer. Nat Med. 2016;22:1303–1313. doi: 10.1038/nm.4198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.4198</ArticleId>
            <ArticleId IdType="pmc">PMC5552044</ArticleId>
            <ArticleId IdType="pubmed">27775704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herzog S, Fink MA, Weitmann K, Friedel C, Hadlich S, Langner S, Kindermann K, Holm T, Böhm A, Eskilsson E, et al.  Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival. Neuro Ooncol. 2015;17:223–242. doi: 10.1093/neuonc/nou216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nou216</ArticleId>
            <ArticleId IdType="pmc">PMC4288523</ArticleId>
            <ArticleId IdType="pubmed">25155357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang SC, Yang CY, Tseng JY, Wang HL, Tung CY, Liu HW, Chen CY, Yeh YC, Chou TY, Yang MH, et al.  ABCG2 localizes to the nucleus and modulates CDH1 expression in lung cancer cells. Neoplasia. 2015;17:265–278. doi: 10.1016/j.neo.2015.01.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neo.2015.01.004</ArticleId>
            <ArticleId IdType="pmc">PMC4372652</ArticleId>
            <ArticleId IdType="pubmed">25810011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhatia P, Bernier M, Sanghvi M, Moaddel R, Schwarting R, Ramamoorthy A, Wainer IW. Breast cancer resistance protein (BCRP/ABCG2) localises to the nucleus in glioblastoma multiforme cells. Xenobiotica. 2012;42:748–755. doi: 10.3109/00498254.2012.662726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/00498254.2012.662726</ArticleId>
            <ArticleId IdType="pmc">PMC3374059</ArticleId>
            <ArticleId IdType="pubmed">22401348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang S, Han L, Wei J, Shi Z, Pu P, Zhang J, Yuan X, Kang C. Combination treatment with doxorubicin and microRNA-21 inhibitor synergistically augments anticancer activity through upregulation of tumor suppressing genes. Int J Oncol. 2015;46:1589–1600. doi: 10.3892/ijo.2015.2841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.2015.2841</ArticleId>
            <ArticleId IdType="pubmed">25625875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calinescu AA, Castro MG. Microtubule targeting agents in glioma. Transl Cancer Res. 2016;5((Suppl 1)):S54–S60. doi: 10.21037/tcr.2016.06.12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/tcr.2016.06.12</ArticleId>
            <ArticleId IdType="pmc">PMC6342473</ArticleId>
            <ArticleId IdType="pubmed">30680290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y, Wang Y, Wu S, Yan Y, Hu Y, Zheng Z, Li J, Wu W. Sulforaphane-cysteine inhibited migration and invasion via enhancing mitophagosome fusion to lysosome in human glioblastoma cells. Cell Death Dis. 2020;11:819. doi: 10.1038/s41419-020-03024-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-03024-5</ArticleId>
            <ArticleId IdType="pmc">PMC7530759</ArticleId>
            <ArticleId IdType="pubmed">33004792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakada M, Nambu E, Furuyama N, Yoshida Y, Takino T, Hayashi Y, Sato H, Sai Y, Tsuji T, Miyamoto KI, et al.  Integrin α3 is overexpressed in glioma stem-like cells and promotes invasion. Br J Cancer. 2013;108:2516–2524. doi: 10.1038/bjc.2013.218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2013.218</ArticleId>
            <ArticleId IdType="pmc">PMC3694230</ArticleId>
            <ArticleId IdType="pubmed">23652300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou J, Yan D, Liu Y, Huang P, Cui H. The roles of integrin α5β1 in human cancer. Onco Targets Ther. 2020;13:13329–13344. doi: 10.2147/OTT.S273803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S273803</ArticleId>
            <ArticleId IdType="pmc">PMC7781020</ArticleId>
            <ArticleId IdType="pubmed">33408483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mallawaaratchy DM, Buckland ME, McDonald KL, Li CC, Ly L, Sykes EK, Christopherson RI, Kaufman KL. Membrane proteome analysis of glioblastoma cell invasion. J Neuropathol Exp Neurol. 2015;74:425–441. doi: 10.1097/NEN.0000000000000187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/NEN.0000000000000187</ArticleId>
            <ArticleId IdType="pubmed">25853691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Renner G, Janouskova H, Noulet F, Koenig V, Guerin E, Bär S, Nuesch J, Rechenmacher F, Neubauer S, Kessler H, et al.  Integrin α5β1 and p53 convergent pathways in the control of anti-apoptotic proteins PEA-15 and survivin in high-grade glioma. Cell Death Differ. 2016;23:640–653. doi: 10.1038/cdd.2015.131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cdd.2015.131</ArticleId>
            <ArticleId IdType="pmc">PMC4986636</ArticleId>
            <ArticleId IdType="pubmed">26470725</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
